NB-001

Summary

Nb-001 (CHEMBL4297305) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including herpes labialis and digeorge syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 264.33 Da · C12H20N6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297305
Name	NB-001
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2815031
Molecular formula	C12H20N6O
Molecular weight	264.33
InChIKey	CVPTTZZCRDVGSU-UHFFFAOYSA-N

SMILES: C1=NC(=C2C(=N1)N(C=N2)CCNCCCCCO)N

IUPAC name: 5-[2-(6-aminopurin-9-yl)ethylamino]pentan-1-ol

Also known as: HTS-09836, Nb-001, NB001, NB-001

Patent coverage: 50 distinct patent families (94 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 89 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Adenylate cyclase type 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADCY1	5	IC50	10000	nM	CHEMBL_ACT_19169039
ADCY1	5	IC50	10000	nM	CHEMBL_ACT_29239564

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
herpes labialis	3	MONDO:0043653	EFO:1001347
DiGeorge syndrome	2	MONDO:0008564	MONDO:0018923

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01324466	PHASE3	COMPLETED	A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)
NCT01695187	PHASE3	UNKNOWN	NB-001 Treatment of Recurrent Herpes Labialis
NCT00453401	PHASE2	COMPLETED	Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
NCT05290493	PHASE2	COMPLETED	NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).